3/4/2026, 6:31:47 AM
HINGHAM, Mass. — March 4, 2026 — Leads & Copy — Microbot Medical Inc. (Nasdaq: MBOT) is applauding the American Medical Association’s (AMA) expanded efforts to protect health care professionals from ionizing radiation.
The AMA adopted a new policy in late 2025 to strengthen protections for health care professionals and trainees who may face occupational radiation exposure. The policy emphasizes continued research into the health effects of cumulative exposure to ionizing radiation, the effectiveness of Personal Protection Equipment (PPE), and education and training to minimize occupational risk to physicians and patients.
Microbot believes this guidance underscores the growing need for solutions that enhance safety in interventional procedures, creating opportunities for technologies like LIBERTY. The LIBERTY System is remotely operated, enabling physicians and staff to perform procedures away from the radiation source. In the ACCESS-PVI Study, using LIBERTY demonstrated a 92% relative reduction in radiation exposure.
Prolonged exposure to radiation often has long-term effects that can lead to health issues, including cancer, cardiovascular disease, reproductive health effects, and cataracts. This risk contributes to staffing shortages in the endovascular space and especially in interventional radiology, which currently ranks number two among specialties with the highest physician shortages. It disproportionately affects women, who often cite radiation exposure and the physical demands of wearing lead aprons as barriers to entering or advancing in the field.
The LIBERTY System’s wireless operated capabilities allow healthcare providers to position themselves away from the radiation source and operate in a seated position, reducing reliance on heavy PPE, thereby lessening musculoskeletal strain.
Harel Gadot, CEO, President and Chairman, stated that prolonged exposure to radiation and staffing shortages are rising concerns among healthcare professionals in the endovascular space. Gadot also stated that these challenges strain an already overburdened health care system, impacting patient care, and widening the skills gap required to address the medical concerns. Gadot believes that LIBERTY can play a major role in addressing these challenges and supporting better care for both providers and their patients.
LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the Limited Market Release (LMR) of the LIBERTY system in late 2025 and plans for a Full Market Release (FMR) at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety.
Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Source: Microbot Medical Inc.
